WillItSurvive
Pharma and healthcare groups · France

Ipsen

ipsen.com ↗

French specialty pharma selling Somatuline, Onivyde, Dysport, and rare disease drugs.

Defensible for now
Assessed 24 July 2026 · Evidence as of 24 July 2026
Real protection, with named pressure against it.
On the recordSince 24 July 2026 · Checkable from within 12 to 24 months · Every call on the record Checkpoint: Onivyde patent litigation ruling (New Jersey district court and PTAB IPR2025-00505)
The call

Ipsen is growing and cash-generative today, with generics and patent fights nibbling at older drugs while new approvals and acquisitions try to outrun them.

Ipsen makes specialty medicines, mostly for cancer and hormonal conditions, and generates steady profits and cash. What could change the picture is the outcome of a patent lawsuit over Onivyde in New Jersey courts and whether generic versions of Somatuline hit the market quickly and successfully; if both go badly for Ipsen and a new drug also fails within the next year, the math on the company would need to be redone.

Why
01
AI pressure: None apparent. AI tools like AlphaFold speed up early drug discovery but cannot bypass patent walls, trials, or FDA approval that protect Ipsen's revenue. Could AI do the core job? Unlikely.
02
Bigger players: AbbVie (Botox), Cipla/InvaGen and CSPC/Conjupro (generic lanreotide and irinotecan). AbbVie's Botox already competes with Dysport, and generic versions of Somatuline and Onivyde are already on the market or in court. Could a giant copy it? No, they are blocked.
03
What protects it. Patent and orphan-drug exclusivity plus manufacturing know-how on complex injectables, backed by strong free cash flow to buy new drugs.
What would change this call
Outcome of Onivyde patent case in New Jersey court and PTAB IPR2025-00505. Shows if Ipsen keeps Onivyde exclusivity or faces generic entry.
Cipla/InvaGen Somatuline generic supply volumes reported through 2026. Indicates how fast lanreotide generics erode Ipsen's rare disease sales.
Kartos Therapeutics deal HSR antitrust clearance and Q3 2026 closing. Shows whether pipeline M&A closes to offset upcoming patent cliffs.
Key numbers
  • FY2025 sales €3.7B, up 10.9% at constant currency (2026-02-12)
  • Core operating margin over 35% in FY2025 (2026-02-12)
  • Somatuline sales still grew 4.3% despite generic entry (2025-12-31)
Named risks
  • Onivyde patent litigation loss could open generic entry against a core oncology franchise. Severity: high
  • Somatuline generic erosion could accelerate if Cipla/InvaGen resolve current supply constraints. Severity: medium
  • Pipeline setbacks such as fidrisertib Phase II failure and Tazverik withdrawal reduce near-term diversification. Severity: medium
  • Kartos Therapeutics acquisition could stall or fail to close if HSR antitrust clearance is delayed. Severity: low
  • IFRS net profit fell in FY2025 due to impairments despite core margin strength, signaling earnings volatility. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
CSPC/Conjupro BiotherapeuticscontestingActive Onivyde patent litigation in New Jersey court and PTAB IPR2025-00505 as of 2026-06-15
Cipla/InvaGencontestingUS generic lanreotide launched 2024 against Somatuline, yet Somatuline still grew 4.3% in FY2025
AbbViecontestingDysport competes with Botox in aesthetics; Ipsen advancing IPN10200 Phase III as of 2026-05-17
Recordatigaining onRecordati rare disease revenue grew 29.7% to EUR 1,081.4M in FY2025, outpacing Ipsen rare disease base rate
AstraZeneca/Roche/Sanofilosing toIpsen is dwarfed in broader oncology and rare disease R&D scale by these larger incumbents per industry analysis
Questions people ask
Is Ipsen profitable in 2026?
Yes. Ipsen reported FY2025 total sales of about EUR 3.7 billion, up 10.9% at constant currency, with core operating income near EUR 1.3 billion (+16.7%) and free cash flow of about EUR 1.0 billion (+29.2%), reported 2026-02-12. IFRS net profit was EUR 445M, down due to impairments.
Who owns Ipsen?
Ipsen trades publicly on Euronext Paris (IPN) with a US ADR (IPSEY), but the Beaufour family retains substantial control through holding vehicles Beech Tree and Highrock, each owning 26.03% of capital as of 2025-12-31, with free float at about 40.08%.
What is Ipsen's biggest competitive threat right now?
Generic and patent erosion of legacy franchises: Cipla/InvaGen launched a US generic lanreotide against Somatuline in 2024, and CSPC/Conjupro Biotherapeutics is contesting Onivyde patents in New Jersey federal court and PTAB IPR2025-00505 as of mid-2026.
Could AI replace Ipsen's drug discovery work?
AI tools like AlphaFold augment early structural biology and target ID, per Ipsen's own discovery team commentary from 2026-04-04, but cannot bypass FDA approval, Orange Book patent exclusivity, or manufacturing know-how. Ipsen published a cautious internal AI pilot post on 2026-07-16, calling it exploratory with no quantified impact disclosed.
Is Somatuline dying due to generics?
Not yet: despite US generic lanreotide entry from Cipla/InvaGen since 2024, Somatuline still grew 4.3% in FY2025 as of 2025-12-31, partly because Ipsen says generic production challenges have constrained rival supply, a dynamic the company itself flagged could reverse.
What is Ipsen's 2026 growth guidance?
On 2026-02-12, Ipsen guided FY2026 total sales growth above 13% at constant currency with core operating margin above 35%, building on FY2025 sales of about EUR 3.7 billion (+10.9% cc) and FY2025 core margin already above 35%.
Timeline
  • 2026-07-22Completed acquisition of Memo Therapeutics AG for potravitug, EUR 200M upfront, up to EUR 700M total
  • 2026-06-29Announced agreement to acquire Kartos Therapeutics for navtemadlin, expected close Q3 2026
  • 2026-04-30EU approval of Ojemda (tovorafenib) for pediatric low-grade glioma
  • 2026-03-31Voluntary withdrawal of Tazverik (tazemetostat) from market
  • 2026-02-12FY2025 results: sales +10.9% cc to about EUR 3.7B, issued FY2026 guidance
  • 2025-12-31Acquisition of ImCheck Therapeutics adding IPN60340 for AML
  • 2025-12-31Phase II FALKON trial of fidrisertib in FOP failed primary endpoint
  • 2025-03-25Issued EUR 500M rated public bond maturing 2032
  • 2024-12-31Sold Increlex (mecasermin) to Euton Pharmaceuticals
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources